
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc has demonstrated a growing reimbursement pipeline, with units increasing from 1,389 in Q4 to 1,669 in Q2, indicating a strengthening demand for its myoelectric orthotics. The company is strategically redirecting growth towards the orthotics and prosthetics market, which is set to account for approximately 22% of revenue in 2024, while also benefiting from the substantial Medicare market. A recent ruling by the CMS to include the MyoPro under Medicare Part B benefits further enhances Myomo's market potential, positioning the company for expansive revenue growth.
Bears say
Myomo has recently revised its 2025 revenue guidance downwards to a range of $40 million to $42 million, significantly lower than the previous estimate of $50 million to $53 million, indicating a decline in financial performance expectations. Additionally, the company has reported a decrease in its backlog of insurance authorized orders to 208, down from 230 in the previous quarter and a peak of 272 in the fourth quarter, reflecting diminished sales momentum. Furthermore, the quality of Myomo's recent marketing efforts and pipeline additions has reportedly been poorer than anticipated, adversely impacting lead generation and conversion rates, which raises concerns about future revenue growth potential.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares